Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Ischemic Cardiomyopathy

Inclusion Criteria: * Age between 18 and 80 y * No option for PCI or CABG (Angiographies evaluated by an independent interventional cardiologist). * Maximal tolerable angina and heart failure medication * NYHA functional classification (I-III) * Signed informed consent Exclusion Criteria: * Severe liver or renal dysfunction or hemorrhagic diseases not suitable for PCI. * Severe cerebral ischemic stroke or cerebral hemorrhage within 6 month. * History with malignant disease within 5 y of inclusion or suspected malignity * Severe heart failure (NYHA functional classification IV) * Diminished functional capacity for other reasons such as COPD, alcoholic cardiomyopathy, or viral myocarditis * Clinical significant anemia, leukopenia, leukocytosis,or thrombocythemia * Clinical significant abnormal prothrombin or partial thromboplastin time or anticoagulation treatment that cannot be paused during treatment * Patients with reduced immune response or treated with immunosuppressive medication * Combined with severe infectious diseases * Pregnant or fertile women * Socially and mentally disabilities